Cargando…

Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data

BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. We thus performed a meta-analys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Wei-Xiang, Wang, Qiong, Jiang, Yan-Ling, Sun, Yuan-Jue, Tang, Li-na, He, Ai-na, Min, Da-liu, Lin, Feng, Shen, Zan, Yao, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568141/ https://www.ncbi.nlm.nih.gov/pubmed/23409011 http://dx.doi.org/10.1371/journal.pone.0055637

Ejemplares similares

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

Overall Survival Prediction of Docetaxel-based Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
por: Nagaraju, Chaitra, et al.
Publicado: (2022)

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients
por: Rothschild, S.I., et al.
Publicado: (2021)

Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival Using Parametric Modelling Methods
por: Harvey, Rebecca C.
Publicado: (2017)

Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer
por: Shimokawa, Mototsugu, et al.
Publicado: (2018)

Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer
por: Whitaker, Kristen D., et al.
Publicado: (2022)

Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
por: Crawford, Jeffrey, et al.
Publicado: (2019)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
por: Minchom, Anna, et al.
Publicado: (2010)

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies
por: Tian, Guangming, et al.
Publicado: (2022)

Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma
por: Hsiao, Pojen, et al.
Publicado: (2019)

Overall survival and second primary malignancies in men with metastatic prostate cancer
por: Mehtälä, Juha, et al.
Publicado: (2020)

Types of second primary cancer influence overall survival in cutaneous melanoma
por: Zheng, Guoqiao, et al.
Publicado: (2021)

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
por: Davies, Jessica, et al.
Publicado: (2017)

Durable Control and Overall Survival Benefit with Focal Reirradiation in Cervical Cancer
por: Amini, Arya, et al.
Publicado: (2015)

Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
por: Kuan, Feng-Che, et al.
Publicado: (2015)

Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer
por: Popat, Sanjay, et al.
Publicado: (2022)

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
por: Aboshi, Masayuki, et al.
Publicado: (2014)

Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial
por: Chen, Yu-Pei, et al.
Publicado: (2015)

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
por: Géczi, Lajos, et al.
Publicado: (2020)

Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
por: Zhang, Yan, et al.
Publicado: (2022)

Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma
por: Amzal, Billy, et al.
Publicado: (2017)

Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not
por: Hemminki, Otto, et al.
Publicado: (2020)

Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis
por: Moik, Florian, et al.
Publicado: (2019)

MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas
por: Fuster-Garcia, Elies, et al.
Publicado: (2020)

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
por: Zhang, Yichen, et al.
Publicado: (2022)

Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data
por: Fornaro, Lorenzo, et al.
Publicado: (2015)

Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?
por: Salati, Massimiliano, et al.
Publicado: (2017)

Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
por: Iacovelli, Roberto, et al.
Publicado: (2014)

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
por: Julian, Cristina, et al.
Publicado: (2022)

Phase II study of sunitinib as second-line treatment for advanced gastric cancer
por: Bang, Yung-Jue, et al.
Publicado: (2010)

Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
por: Chan, Sik-Kwan, et al.
Publicado: (2022)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
por: Cui, Shaohua, et al.
Publicado: (2016)

The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
por: Zhang, Jian-Wei, et al.
Publicado: (2014)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008
por: Wood, L.
Publicado: (2009)

First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma
por: Wang, Xuechen, et al.
Publicado: (2021)

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
por: Zhang, Zewei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gmfi4lf894ksoihpukl866140v